Table 4.
Univariate analysis of prognostic factors for progression-free survival
| Univariate analysis(Logrank) | Multivariate analysis (Cox) | |||||
|---|---|---|---|---|---|---|
| Characteristics (reference) | HR | 95% CI | P- value | HR | 95% CI | P-value |
| Patient Characteristics | ||||||
| Gender (male vs female) | 1.4 | 0.6-3.5 | 0.4 | - | - | - |
| Age (> 60 vs < 60 years) | 0.5 | 0.3-0.8 | 0.02 | 0.6 | 0.3-1.1 | 0.1 |
| Pretreatment hemoglobin level (< 120 vs > 120 g/L) | 1 | 0.6-1.6 | 0.9 | - | - | - |
| Initial weight loss (> 10% vs < 10%) | 1.3 | 0.8-2.1 | 0.3 | - | - | - |
| Dysphagia (mild vs liquid) | 1.2 | 0.7-2.1 | 0.4 | - | - | - |
| Karnofsky Performance status (< 80 vs 90-100) | 0.6 | 0.3-0.9 | 0.01 | - | - | - |
| Tumor Characteristics | ||||||
| Histology (SCCE vs ACE) | 1 | 0.6-1.7 | 0.9 | - | - | - |
| T Stage (3-4 vs 1-2) | 1 | 0.5-1.8 | 0.9 | - | - | - |
| N Stage (1 vs 0) | 1.3 | 0.8-2 | 0.4 | - | - | - |
| M stage (1 vs 0) | 1.8 | 1-3.1 | < 0.05 | 1.7 | 0.9-3.4 | 0.1 |
| Treatment-related Characteristics | ||||||
| Objective response to CRT (no vs yes) | 3.3 | 2.0-5.0 | < 0.0001 | 4.8 | 2.4-9.4 | < 0.0001 |
| Definitive CRT vs Preoperative CRT | 2.5 | 1.25-5.0 | 0.01 | 2.4 | 1.2-4.8 | < 0.02 |
| Antibodies | ||||||
| Anti-p53 (positive vs negative) | 1.8 | 1.05-2.9 | 0.03 | 2 | 1-3.9 | 0.04 |
| Anti-Ras (positive vs negative) | 0.8 | 0.5-1.4 | 0.5 | - | - | - |
Abbreviations: ACE, adenocarcinoma of the esophagus; CI, confidence interval; CRT, chemoradiotherapy; HR, hazard ratio; SCCE, squamous cell carcinoma of the esophagus